Verona pharma reports fourth quarter and full year 2024 financial results and provides corporate update

Ohtuvayre tm (ensifentrine) recorded net product sales of $36.6 million in q4 and $42.3 million in 2024

VRNA Ratings Summary

VRNA Quant Ranking